A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.
Latest from Elizabeth Cairns
The UK group began more clinical trials last year than any other company, a new report from Citeline has found.
Unlike previous deals in this space which were mostly to do with discovering new compounds, the big pharma is paying $150m upfront to license a specific product.
The French major enjoys swift growth from Beyfortus among others, and is unworried by future competition.
The new company, Rhine Pharma, hopes to avoid the isotope production issues that have dogged other radiopharmaceutical developers.
A Phase II failure with an old asset throws the company’s biomarker-driven strategy into doubt.
Two of 2030’s forecast blockbuster obesity drugs are facing binary readouts by the end of the year. Here’s what that could mean for their developers, Novo Nordisk and Amgen.